Abstracts Archive - Page 1761 of 2425 - ACR Meeting Abstracts

Abstract Number: 1075 • 2015 ACR/ARHP Annual Meeting
The Scleroderma Lung Study II (SLS II) Shows That Both Oral Cyclophosphamide (CYC) and Mycophenolate Mofitil (MMF) Are Efficacious in Treating Progressive Interstitial Lung Disease (ILD) in Patients with Systemic Sclerosis (SSc)
Philip J. Clements¹, Donald Tashkin¹, Michael Roth¹, Dinesh Khanna², Daniel E. Furst³, Chi-hong Tseng¹, Elizabeth R. Volkmann¹ and Robert Elashoff⁴, ¹Medicine, University of California Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ²Medicine, University of Michigan, Ann Arbor, MI, ³Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁴Biomath, University of California Los Angeles, David Geffen School Of Medicine, Los Angeles, CA
Background/Purpose: Demonstrate that the course of forced vital capacity (FVC) over 2-years was better in SSc patients with symptomatic ILD treated with oral MMF for…
Abstract Number: 1076 • 2015 ACR/ARHP Annual Meeting
Safety and Tolerability of Cyclophosphamide Versus Mycophenolate for Systemic Sclerosis-Related Interstitial Lung Disease
Elizabeth R. Volkmann¹, Michael Roth², Robert Elashoff³, Philip J. Clements¹, Daniel E. Furst², Dinesh Khanna⁴, Jonathan Goldin⁵, Donald Tashkin¹ and Scleroderma Lung Study II Group, ¹Medicine, University of California Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ²Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ³Biomathematics, University of California, Los Angeles, Los Angeles, CA, ⁴Medicine, University of Michigan, Ann Arbor, MI, ⁵David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA
Background/Purpose: Interstitial lung disease (ILD) is the leading cause of death in patients with systemic sclerosis (SSc). Although cyclophosphamide (CYC) demonstrated beneficial treatment effects at…
Abstract Number: 1077 • 2015 ACR/ARHP Annual Meeting
High Levels of CCL-18 Are Associated with Deterioration of Lung Function, Increased Annual Fibrosis Progression Rate and Decreased Survival in Systemic Sclerosis
Anna-Maria Hoffmann-Vold^1,2, Anders Heiervang Tennøe², Oyvind Midtvedt¹, Torhild Garen³, May Brit Lund⁴, Trond Mogens Aalokken⁵, Cathrine Brunborg⁶, Thor Ueland² and Øyvind Molberg⁷, ¹Rheumatology, Oslo University Hospital, Oslo, Norway, ²Institute of clinical medicine, University of Oslo, Oslo, Norway, ³Rheumatology, Department of Rheumatology, Oslo University Hospital, Oslo, Norway, ⁴Respiratory Diseases, Oslo University Hospital, Oslo, Norway, ⁵Radiology, Oslo University Hospital, Oslo, Norway, ⁶Biostatistics, Epidemiology and Health Economics, Oslo University Hospital, Oslo, Norway, ⁷Department of Rheumatology, Institute of Clinical Medicine, Oslo University Hospital, Oslo, Norway
Background/Purpose: Systemic sclerosis (SSc) carries high risk for progressive interstitial lung disease (ILD), but biomarkers for individual risk stratification are largely missing. There is an…
Abstract Number: 1078 • 2015 ACR/ARHP Annual Meeting
CXCL4 Does Not Predict Extent or Progression of Interstitial Lung Disease in Systemic Sclerosis
Elizabeth R. Volkmann¹, Donald P. Tashkin¹, Michael Roth¹, Chi-hong Tseng¹, Holly LeClair², Philip J. Clements¹, Daniel E. Furst³, Maureen D Mayes⁴, Julio Charles⁵, Dinesh Khanna⁶, Robert Elashoff⁷, Shervin Assassi⁸ and Scleroderma Lung Study II Group, ¹Medicine, University of California Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ²University of California Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ³Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁴University of Texas - Houston Medical School, Houston, TX, ⁵Internal Medicine/Rheumatology, University of Texas - Houston Medical School, Houston, TX, ⁶University of Michigan, Ann Arbor, MI, ⁷Biomathematics, University of California, Los Angeles, Los Angeles, CA, ⁸Rheumatology, University of Texas Medical School at Houston, Houston, TX
Background/Purpose: Increased circulatory levels of the chemokine CXCL4 have been associated with the presence of pulmonary fibrosis (PF) by HRCT in an observational study of…
Abstract Number: 1079 • 2015 ACR/ARHP Annual Meeting
The Potential Effect on Recruitment of Restricting Skin Scores Eligibility Criteria in Early Diffuse Scleroderma Trials
Robyn T. Domsic¹, Dinesh Khanna², Mary Lucas³, Virginia D. Steen⁴, Daniel E. Furst⁵, Robert Lafyatis⁶ and Thomas A. Medsger Jr.⁷, ¹Medicine - Rheumatology, University of Pittsburgh, Pittsburgh, PA, ²Division of Rheumatology, University of Michigan, Ann Arbor, MI, ³Medicine, University of Pittsburgh Scleroderma Center, Pittsburgh, PA, ⁴Rheumatology, Georgetown University Medical Center, Washington, DC, ⁵Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁶Boston University School of Medicine, Boston, MA, ⁷Department of Medicine/Rheumatology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: There is increasing interest in cohort enrichment for clinical trials of early diffuse SSc (dcSSc). Recent EUSTAR database analysis (Maurer et al. 2015)…
Abstract Number: 1080 • 2015 ACR/ARHP Annual Meeting
Modified Rodnan Skin Score Thresholds for the Optimization of Cohort Enrichment in Clinical Trials in Skin Fibrosis in Patients with Diffuse Cutaneous Systemic Sclerosis
Rucsandra Dobrota¹, Britta Maurer¹, Nicole Graf², Suzana Jordan³, Carmen Marina Mihai⁴, Otylia Kowal-Bielecka⁵, Yannick Allanore⁶, Oliver Distler¹ and EUSTAR co-authors, ¹Division of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ²graf biostatistics, Winterthur, Switzerland, ³Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ⁴Department of Internal Medicine and Rheumatology, Cantacuzino Hospital, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania, ⁵Department of Rheumatology and Internal Medicine, Medical University of Bialystok, Bialystok, Poland, ⁶Department of Rheumatology, University Paris Descartes and Cochin Hospital, Paris, France
Background/Purpose: The modified Rodnan skin score (mRSS) is the major outcome measure for skin fibrosis in clinical trials (CT) in diffuse cutaneous scleroderma (dcSSc). Traditionally,…
Abstract Number: 1081 • 2015 ACR/ARHP Annual Meeting
Administration of Patient Reported Outcome Measurement Information System (PROMIS) Instruments By Computer Adaptive Testing in Patients with Systemic Vasculitis
Gunnar Tomasson¹, John T. Farrar², David Cuthbertson³, Carol McAlear⁴, Susan Asdown⁵, Don Gebhart⁶, Georgia Lanier⁷, Nataliya Milman⁸, Jacqueline Peck⁹, Joanna Robson¹⁰, Simon Carette¹¹, Gary S. Hoffman¹², Nader A. Khalidi¹³, Curry L. Koening¹⁴, Carol A. Langford¹², Larry W. Moreland¹⁵, Paul A. Monach¹⁶, Christian Pagnoux¹¹, Ulrich Specks¹⁷, Antoine G. Sreih¹⁸, Steven R. Ytterberg¹⁹ and Peter A. Merkel⁴, ¹Dept of Public Health Sciences, University of Iceland, Reykiavik, Iceland, ²Universitiy of Pennsylvania, Philadelphia, PA, ³Biostatistics and Informatics, Department of Pediatrics, University of South Florida, Tampa, FL, ⁴Penn Vasculitis Center, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ⁵NONE, Branbury, United Kingdom, ⁶NONE, Columbus, OH, ⁷NONE, Framingham, MA, ⁸Division of Rheumatology, University of Ottawa, Ottawa, ON, Canada, ⁹Oxford University, Oxford, United Kingdom, ¹⁰Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Sciences, University of Oxford, University of Oxford, Oxford, United Kingdom, ¹¹Mount Sinai Hospital, Toronto, ON, Canada, ¹²Rheumatology, Cleveland Clinic, Cleveland, OH, ¹³McMaster University, Hamilton, ON, Canada, ¹⁴Division of rheumatology, George E. Wahlen Department of Veterans Affairs Medical Center Salt Lake City and University of Utah, University of Utah School of Medicine, Salt Lake City, UT, ¹⁵Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ¹⁶Rheumatology, Boston University School of Medicine, Boston, MA, ¹⁷Division of Pulmonary and Critical Care Medicine, Mayo Clinic College of Medicine, Rochester, MN, ¹⁸Department of Rheumatology, University of Pennsylvania, Philadelphia, PA, ¹⁹Rheumatology Division, Mayo Clinic, Rochester, MN
Background/Purpose: Currently-used outcome measures in vasculitis insufficiently capture the life impact of systemic vasculitis from patients' perspectives. The Patient Reported Outcome Measurement Information System…
Abstract Number: 1082 • 2015 ACR/ARHP Annual Meeting
ANCA-Negative and Myeloperoxidase-ANCA-Positive Patients with Granulomatosis with Polyangiitis: Clinical Manifestations and Risk of Relapse
Eli Miloslavsky¹, Na Lu², Sebastian Unizony³, Hyon K. Choi³, Peter A. Merkel⁴, Philip Seo⁵, Robert F. Spiera⁶, Carol A. Langford⁷, Gary S. Hoffman⁷, Cees Kallenberg⁸, E. William St.Clair⁹, Nadia Tchao¹⁰, Fernando Fervenza¹¹, Paul A. Monach¹², Ulrich Specks¹³ and John H. Stone¹⁴, ¹Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Boston, MA, ²Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ³Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁴Penn Vasculitis Center, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ⁵Division of Rheumatology, Johns Hopkins, Baltimore, MD, ⁶Rheumatology, Hospital for Special Surgery, New York, NY, ⁷Rheumatology, Cleveland Clinic, Cleveland, OH, ⁸Rheumatology/Clin Immunol AA21, Univer Med Center Groningen, Groningen, Netherlands, ⁹Rheumatology and Immunology, Duke University, Durham, NC, ¹⁰ITN, San Francisco, CA, ¹¹Mayo Clinic, Rochester, MN, ¹²Rheumatology, Boston University School of Medicine, Boston, MA, ¹³Division of Pulmonary and Critical Care Medicine, Mayo Clinic College of Medicine, Rochester, MN, ¹⁴Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA
Background/Purpose: Recent studies in ANCA-associated vasculitis (AAV) have suggested that classification based on ANCA type (PR3 versus MPO) may represent a more clinically relevant division…
Abstract Number: 1083 • 2015 ACR/ARHP Annual Meeting
Nationwide Trends in Hospitalization and in-Hospital Mortality Associated with Granulomatosis with Polyangiitis (GPA)
Zachary Wallace¹, John H. Stone², Hyon K. Choi³, Na Lu³, Sebastian Unizony³ and Eli Miloslavsky⁴, ¹Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ³Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁴Division of Rheumatology, Massachusetts General Hopsital, Boston, MA
Background/Purpose: Granulomatosis with polyangiitis (GPA) is associated with severe end-organ damage (e.g., renal failure) and treatment-related complications (e.g., severe infection) which often lead to hospitalization…
Abstract Number: 1084 • 2015 ACR/ARHP Annual Meeting
Improved Survival in Granulomatosis with Polyangiitis: A General Population-Based Study
Zachary Wallace¹, Sebastian Unizony², Na Lu², Hyon K. Choi² and John H. Stone³, ¹Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Boston, MA, ²Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ³Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA
Background/Purpose: Granulomatosis with polyangiitis (GPA) is associated with an increased risk of mortality. Advances in diagnosis and treatment strategies are thought to improve outcomes in…
Abstract Number: 1085 • 2015 ACR/ARHP Annual Meeting
Levamisole Triggers Neutrophil Extracellular Trap Formation through Muscarinic Receptors in Patients with Drug-Induced Vasculitis
Peter C. Grayson¹, Carmelo Carmona-Rivera², Meryl Waldman³, Karran Phillips⁴, Venkataraman Subramaniam⁵, Paul Thompson⁶, Jonathan D. Graf⁷ and Mariana J. Kaplan¹, ¹National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ²Systemic Autoimmunity Branch/ NIAMS, National Institutes of Health, Bethesda, MD, ³NIDDK, National Institutes of Health, Bethesda, MD, ⁴NIDA, National Institutes of Health, Baltimore, MD, ⁵Biochemistry and Molecular Pharmacology, University of Massachusetts, Worcester, MA, ⁶Biochemistry and Molecular Pharmacology, University of Masshachussetts, Worcester, MA, ⁷Rosalind Russell / Ephraim P. Engleman Rheumatology Research Center, University of California, San Francisco, San Francisco, CA
Background/Purpose: Levamisole, an anti-helminth drug, has been implicated in cases of drug-induced autoimmunity in humans exposed to adulterated cocaine. Clinical manifestations of levamisole-induced autoimmunity include…
Abstract Number: 1086 • 2015 ACR/ARHP Annual Meeting
Does Adding Azathioprine to Glucocorticoid Induction Increase the Remission Rate and Prevent Relapses in Patients with Systemic Necrotizing Vasculitides without Poor-Prognosis Factors? a Multicenter, Double-Blind Randomized Controlled Trial
Xavier Puéchal¹, Christian Pagnoux², Gabriel Baron³, Thomas Quémeneur⁴, Antoine Néel⁵, Christian Agard⁵, François Lifermann⁶, Eric Liozon⁷, Marc Ruivard⁸, Pascal Godmer⁹, Nicolas Limal¹⁰, Arsène Mékinian¹¹, Thomas Papo¹², Anne-Marie Ruppert¹³, Anne Bourgarit-Durand¹⁴, Boris Bienvenu¹⁵, Loïck Geffray¹⁶, Jean-Luc Saraux¹⁷, Elisabeth Diot¹⁸, Bruno Crestani¹², Xavier Delbrel¹⁹, Laurent Sailler²⁰, Pascal Cohen¹, Véronique Le Guern²¹, Benjamin Terrier¹, Matthieu Groh²¹, Claire Le Jeunne²¹, Luc Mouthon²¹, Philippe Ravaud³ and Loïc Guillevin for The French Vasculitis Study Group²¹, ¹Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, Paris, France, ²Mount Sinai Hospital, Toronto, ON, Canada, ³Hôpital Hôtel Dieu, Paris, France, ⁴CH Valenciennes, Valenciennes, France, ⁵CHU Nantes, Nantes, France, ⁶CH Dax, Dax, France, ⁷CHU Limoges, Limoges, France, ⁸CHU Clermont-Ferrand, Clermont–Ferrand, France, ⁹CH Vannes, Vannes, France, ¹⁰CHU Créteil, Créteil, France, ¹¹Service de médecine interne. Hôpital Saint-Antoine., Paris, France, ¹²CHU Bichat, Paris, France, ¹³CHU Tenon, Paris, France, ¹⁴CHU Bondy, Bondy, France, ¹⁵Internal Medicine, Hospital Caen, Caen, France, ¹⁶CH Lisieux, Lisieux, France, ¹⁷CH Eaubonne, Eaubonne, France, ¹⁸CHU Tours, Tours, France, ¹⁹CH Pau, Pau, France, ²⁰CHU Toulouse, Toulouse, France, ²¹National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France
Background/Purpose: Glucocorticoids (GC) achieve remission in most patients with systemic necrotizing vasculitides (SNVs) without poor-prognosis factors based on the 1996 Five-Factor Score (FFS; comprising creatininemia…
Abstract Number: 1087 • 2015 ACR/ARHP Annual Meeting
“It Was Just My Right Pace”: A Qualitative Study Exploring Yoga Practice in Adults with Rheumatoid Arthritis
Heather Greysen, School of Nursing, University of California San Francisco, San Francisco, CA
Background/Purpose: Physical activity is reported to improve physical function and reduce disease symptoms in adults with rheumatoid arthritis (RA); however adults with RA are less…
Abstract Number: 1088 • 2015 ACR/ARHP Annual Meeting
Effect of Training on Knee Torsional Stiffness and Its Relationship to Tibial Compressive and Anterior Shear Forces in Recreational Female Runners
Bhushan Thakkar¹ and D. S. Blaise Williams III², ¹PHYSICAL THERAPY, VIRGINIA COMMONWEALTH UNIVERSITY, RICHMOND, VA, ²Physical Therapy, Virginia Commonwealth University, Richmond, VA
Background/Purpose: 42 million Americans participate annually in running. In 2014, the half marathon was the most popular distance with a total of 61% females (1.2…
Abstract Number: 1089 • 2015 ACR/ARHP Annual Meeting
Responsiveness of Physical Activity Measures Following Exercise Intervention in Individulas after Total Knee Arthroplasty
Gustavo J. Almeida¹, James J. Irrgang² and Sara R. Piva¹, ¹Physical Therapy, University of Pittsburgh, Pittsburgh, PA, ²Orthopaedic Surgery, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Few instruments that measure physical activity (PA) can accurately quantify PA performed at light and moderate intensities, which is particularly relevant to older adults…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].